Effect of Beta Blockers (Metoprolol or Propranolol) on Effect of Simvastatin in Lowering C-Reactive Protein in Acute Myocardial Infarction

The Role of Inflammation in Myocardial Infarction

“…In contrast, in another study carvedilol (a beta-blocker well known for its anti-inflammatory and antioxidant properties) [234] was found to suppress plasma levels of TNF-α and IL-6 in ischemic and nonischemic dilated cardiomyopathy, but with effects more marked in nonischemic patients [235]. It is important to note here that there is evidence against the coadministration of some beta-blockers with statins, as the benefit of the latter might be reduced in acute MI patients [236]. The researchers demonstrated that metoprolol or propranolol might reduce the anti-inflammatory effects of simvastatin (which suppresses CRP), hence their simultaneous use (a very common combination in clinical use) might lead to a reduced statin-mediated beneficial effect.…”

HDL levels and oxidizability during myocardial infarction are associated with reduced endothelial-mediated vasodilation and nitric oxide bioavailability

“…A more detailed description is published elsewhere [9]. Briefly, the admission criteria included: (i) less than 24 h from the onset of symptoms of MI, (ii) ST-segment elevation of at least 1 mm (frontal plane) or 2 mm (horizontal) in contiguous leads, and (iii) myocardial necrosis, as evidenced by an increase to at least one value above the 99th percentile above the reference limit of CK-MB (25 U/L) and troponin I (0.04 ng/mL), followed by a decline of both.…”

Editorial The effects of statins on blood pressure: current knowledge and future perspectives

“…The authors have already observed similar effects in two other studies with a 2-week period of statin administration [17, 18]. Yet, a reduction in heart rate and BP has been reported in patients with hypertension and type-2 diabetes with the concomitant administration of simvastatin and metoprolol [19], and other studies evaluated the effects of such combined therapy on C-reactive protein levels [20]. We cannot exclude that therapeutic modulation of enhanced inflammation and/or atherogenic dyslipidaemia may contribute to the beneficial effect shown by simvastatin on blood pressure, especially considering that the study by Owczarek et al .…”